290 related articles for article (PubMed ID: 36211821)
1. Prognostic Signature Development on the Basis of Macrophage Phagocytosis-Mediated Oxidative Phosphorylation in Bladder Cancer.
Qu G; Xu Y; Lu Z; Nie H; Tang C; Hou J; Wen X
Oxid Med Cell Longev; 2022; 2022():4754935. PubMed ID: 36211821
[TBL] [Abstract][Full Text] [Related]
2. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
3. Identification of a Nine-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival of Pancreatic Cancer.
Wu M; Li X; Zhang T; Liu Z; Zhao Y
Front Oncol; 2019; 9():996. PubMed ID: 31612115
[No Abstract] [Full Text] [Related]
4. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
[TBL] [Abstract][Full Text] [Related]
5. Development and Validation of a Hypoxia-Related Signature for Predicting Survival Outcomes in Patients With Bladder Cancer.
Zhang F; Wang X; Bai Y; Hu H; Yang Y; Wang J; Tang Y; Ma H; Feng D; Li D; Han P
Front Genet; 2021; 12():670384. PubMed ID: 34122523
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of a prognostic immune-related lncRNA signature in bladder cancer.
Zhao K; Zhang Q; Zeng T; Zhang J; Song N; Wang Z
Transl Androl Urol; 2021 Mar; 10(3):1229-1240. PubMed ID: 33850758
[TBL] [Abstract][Full Text] [Related]
7. Construction and Validation of a Prognostic Model Based on Pyroptosisrelated Genes in Bladder Cancer.
Shen C; Han C; Li Z; Yan Y; Li C; Chen H; Fan Z; Hu H
Comb Chem High Throughput Screen; 2023 Oct; ():. PubMed ID: 37849225
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Novel Glycolysis-Related LncRNA Signature for Predicting Overall Survival in Patients With Bladder Cancer.
Zheng Z; Lai C; Li W; Zhang C; Ma K; Yao Y
Front Genet; 2021; 12():720421. PubMed ID: 34490046
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
[TBL] [Abstract][Full Text] [Related]
11. Identification of a three-gene expression signature and construction of a prognostic nomogram predicting overall survival in lung adenocarcinoma based on TCGA and GEO databases.
Zhou Y; Gao S; Yang R; Du C; Wang Y; Wu Y
Transl Lung Cancer Res; 2022 Jul; 11(7):1479-1496. PubMed ID: 35958325
[TBL] [Abstract][Full Text] [Related]
12. A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
Sun JX; Liu CQ; Xu JZ; An Y; Xu MY; Zhong XY; Zeng N; Ma SY; He HD; Zhang ZB; Wang SG; Xia QD
Front Immunol; 2022; 13():908068. PubMed ID: 35898492
[TBL] [Abstract][Full Text] [Related]
13. Identification of necroptosis-related long non-coding RNAs prognostic signature and the crucial lncRNA in bladder cancer.
Sun YF; Chen L; Xia QJ; Wang TH
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10217-10234. PubMed ID: 37269345
[TBL] [Abstract][Full Text] [Related]
14. A novel CD8
Lin F; Ke ZB; Xue YT; Chen JY; Cai H; Lin YZ; Li XD; Wei Y; Xue XY; Xu N
Inflamm Res; 2023 Aug; 72(8):1665-1687. PubMed ID: 37578544
[TBL] [Abstract][Full Text] [Related]
15. Establishment and Validation of a Tumor Microenvironment Prognostic Model for Predicting Bladder Cancer Survival Status Based on Integrated Bioinformatics Analyses.
Chen Q; Yin G; He X; Jiang T; Zhou H; Wu Y; Li Y
Evid Based Complement Alternat Med; 2022; 2022():4351005. PubMed ID: 36225190
[TBL] [Abstract][Full Text] [Related]
16. A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer.
Wang W; Zhang X; Jiang S; Xu P; Chen K; Li K; Wang F; Le X; Zhang K
Front Immunol; 2023; 14():1187286. PubMed ID: 37691944
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a metastasis-related Gene Signature for predicting the Overall Survival in patients with Pancreatic Ductal Adenocarcinoma.
Wu M; Li X; Liu R; Yuan H; Liu W; Liu Z
J Cancer; 2020; 11(21):6299-6318. PubMed ID: 33033514
[No Abstract] [Full Text] [Related]
18. Development and Validation of a Prognostic Gene Signature Correlated With M2 Macrophage Infiltration in Esophageal Squamous Cell Carcinoma.
Yao J; Duan L; Huang X; Liu J; Fan X; Xiao Z; Yan R; Liu H; An G; Hu B; Ge Y
Front Oncol; 2021; 11():769727. PubMed ID: 34926275
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of a novel glycolysis-related gene expression signature for gastrointestinal cancer in the Asian population.
Xia R; Tang H; Shen J; Xu S; Liang Y; Zhang Y; Gong X; Min Y; Zhang D; Tao C; Wang S; Zhang Y; Yang J; Wang C
Cancer Cell Int; 2021 Mar; 21(1):154. PubMed ID: 33663535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
